Study of SHR-A1811 plus pertuzumab before surgery for HER2+ breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of two targeted drugs (SHR-A1811 and pertuzumab) given before surgery to shrink HER2-positive breast cancer. It aims to see if this approach improves outcomes for patients with early-stage but high-risk disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old and in good general health (ECOG 0-1).
- You have HER2-positive invasive breast cancer that is stage T2 to T4 (tumor size at least 2 cm or more) and may have spread to lymph nodes but not to other parts of the body (M0).
- You have not received any prior chemotherapy, hormone therapy, or targeted therapy for this breast cancer.
- You do not have another active cancer, uncontrolled heart problems, or a history of allergic reactions to the study drugs.
- Your heart function is normal (LVEF 50% or higher) and your blood counts and organ function are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two anti-HER2 medicines given before surgery to shrink HER2-positive early breast cancer. It aims to see which treatment works better as “neoadjuvant” therapy to improve outcomes while keeping you safe.
This trial tests SHR-A1811 given before surgery (neoadjuvant treatment) for breast cancer that is hormone-receptor positive (HR-positive) and HER2-low. It aims to shrink or control the cancer early and see how well this approach works compared with standard care.
This Phase 2 trial compares nab-PH plus pyrrolitinib versus TCbHP as treatment given before breast surgery. It aims to see which option works better and is safe for people with HER2-positive invasive breast cancer.
This study tests a new drug called SHR-A1811 combined with pertuzumab (Perjeta) before surgery for patients with HER2-positive breast cancer that has not spread beyond the breast and nearby lymph nodes. The goal is to shrink the cancer before surgery and improve outcomes.
This trial tests a new drug called SHR-A1811 combined with pertuzumab given before surgery to shrink tumors in people with early or locally advanced, hormone receptor-positive and HER2-positive breast cancer. It is designed to see if this combination can help reduce tumor size better.
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
Hear when a new Breast Cancer Early Stage Breast Cancer (Stage 1-3) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.